Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Date:8/3/2009

2009 and reimbursements for UDB-related development expenses, pursuant to MAP Pharmaceuticals' license agreement with AstraZeneca AB. On July 8, 2009, the company received notice from AstraZeneca of the termination of the license agreement, effective immediately. As a result, the remaining unamortized deferred revenue of $33.1 million will be recognized as collaboration revenue in the third quarter of fiscal 2009.

Research and development expenses for the quarter and six months ended June 30, 2009 were $9.6 million and $23.7 million, respectively, compared to $13.0 million and $24.8 million, respectively, for the same periods in 2008. The decreases in research and development expenses were driven primarily by decreases in clinical and other project expenses to support the UDB Phase 3 clinical program, partially offset by increases in clinical and other project expenses to support the LEVADEX Phase 3 clinical program, and in personnel-related expenses to support these clinical programs.

Sales, general and administrative expenses for the quarter and six months ended June 30, 2009 were $3.4 million and $6.2 million, respectively, compared to $3.2 million and $6.3 million, respectively, for the same periods in 2008. For the three months ended June 30, 2009 compared to the same period in 2008, the increase was related primarily to increases in personnel-related expenses, stock-based compensation and other miscellaneous fees.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of June 30, 2009 of $54.8 million, compared to $44.7 million as of December 31, 2008. In addition, accounts receivables were $5.1 million at June 30, 2009, compared to $0 at December 31, 2008, due to the collaboration with AstraZeneca.

For the quarter and six months ended June 30, 2009, non-cash share-based compensation and depreciation were approximately $1.7 million and $3.3 million, respectiv
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... in the Faculty of Medicine & Dentistry demonstrate that ... neurons in parts of the brain responsible for cognition ... sclerosis, is a fatal neurodegenerative disease that eventually leaves ... has shown about 50 per cent of patients with ...
... Sept. 16 (HealthDay News) -- Although the U.S. Centers for ... leading cause of death for people aged 15 to 24 ... the mental health treatment they need. The researchers found ... mental health professional through their health care network, and only ...
... 16, 2011 A study by epidemiologists at Wake ... high intake of calcium causes prostate cancer among African-American ... "High dietary intake of calcium has long been ... observation has been elusive," said Gary G. Schwartz, Ph.D., ...
... role for a new type of T cell in the ... to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery ... may be possible to treat inflammation and autoimmune diseases by ... published this week in Science. "The discovery that ...
... Gordon HealthDay Reporter , THURSDAY, Sept. 15 (HealthDay ... may lower your risk of stroke more than other fruits ... day of white fruits and vegetables consumed led to a ... and pears were the most commonly consumed "white fruit," according ...
... on Capitol Hill today demonstrated that the Great Recession ... workers, although programs such as the federal Senior Community ... valuable benefits to this disadvantaged demographic group. ... National Employ Older Workers Week was titled, "Older ...
Cached Medicine News:Health News:MRI research demonstrates ALS attacks multiple parts of the brain 2Health News:Few Suicidal Teens Get the Help They Need 2Health News:Genetics may explain why calcium increases risk for prostate cancer 2Health News:T cells making brain chemicals may lead to better treatments for inflammation, autoimmune diseases 2Health News:An Apple a Day Really May Keep the Doctor Away 2Health News:An Apple a Day Really May Keep the Doctor Away 3Health News:Congressional briefing sheds light on poor seniors' employment struggles 2Health News:Congressional briefing sheds light on poor seniors' employment struggles 3
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health care supply ... IT value-added reseller (VAR) national contracts that expand its ... services at lower costs. These include manufacturer product and ... initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Nano Mask, Inc. (NMI) (Pink Sheets: NANM ... on emergency and critical care as well as infection ... a distribution agreement with a Saudi Arabia-based medical products ... exclusive basis to: The Kingdom of Saudi Arabia, United ...
... Aug. 25, 2011 The U.S. Food and Drug Administration ... attacks of a rare condition called hereditary angioedema (HAE) in ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the improper function of a protein called C1 inhibitor, which ...
Cached Medicine Technology:Nano Mask Enters Into Four-Year Distribution Agreement With Saudi Medical Products Distributor 2FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema 2
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Medicine Products: